A Phase II Study of Irinotecan, Capecitabine and Avastin in Patients With Metastatic Colorectal Cancer, Who Have Progressed After 1ST Line Therapy With Folfox/Avastin.
The aim of this phase II study is to evaluate the efficacy of the combination XELIRI/AVASTIN
in patients with mCRC, who have progressed in first line treatment with FOLFOX/AVASTIN. For
AVASTIN was selected the dosing schedule of the trials TREE 1 and 2 [17], where Avastin was
combined with capecitabine and oxaliplatin in a three weeks schedule and with adaptation of
the dose in the 7,5 mg/kg
Interventional
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Objective Response Rate
up to 6 months
No
Vassilis Georgoulias, MD
Principal Investigator
University Hospital of Crete, Dep of Medical Oncology
Greece: National Organization of Medicines
CT/05.35
NCT00717990
April 2008
December 2012
Name | Location |
---|